RESUMEN
Background: Pain is a complex experience consisting of physiological and psychological response to a noxious stimulus. Analgesics like opiates and non-steroidal anti-inflammatory drugs are commonly used for relieving pain but are associated with various unwanted side effects; therefore this study was conducted by using Origanum vulgare for their analgesic efficacy.Methods: In vivo model used was tail flick method. Origanum vulgare (84 mg/kg p.o) was administered in mice. The analgesic activity was studied by recording the reaction time after administration of the drug at frequent intervals up to 3 hours. The results were analysed by ANOVA and Tukey’s test. P-value <0.05 was considered as significant. Pentazocine showed statistically prolongation in the reaction time after 30 min as compared to Origanum vulgare.Results: In tail flick method, pentazocine showed statistically significant increase in the reaction time after 30 min of administration as compared to control group. However, Origanum vulgare in a dose of 84 mg/kg showed significant increase in the reaction time after 30 min of administration as compared to control group. On comparing pentazocine and Origanum vulgare, pentazocine showed highly significant increase in the reaction time after 30 min as compared to Origanum vulgare at 84 mg/kg dose.Conclusions: From the present study, it was concluded that extract of Origanum vulgare exerted analgesic activity in both the models. However, it was less potent than pentazocine. Thus, Origanum vulgare can be used in mild to moderate painful conditions.
RESUMEN
Background: Metabolic syndrome is described as the clustering of obesity, aberrant glucose metabolism, dyslipidemia and hypertension. A characteristic pattern, termed diabetic dyslipidemia, consists of low HDL, increased triglycerides and postprandial lipemia. This pattern is most frequently seen in type 2 diabetes and may be a treatable risk factor for subsequent cardiovascular disease. This study was designed to compare the hypolipidemic activity of Coriandrum sativum L. with the standard antidiabetic drug, metformin in streptozotocin induced diabetic rats.Methods: Streptozotocin (STZ) was used to induce diabetes in the rats. The hypolipidemic activity of Coriandrum sativum seed extract was compared to the standard drug metformin. 4 groups (n=8) (normal control, diabetic control, streptozotocin+Coriandrum sativum and streptozotocin+metformin). The drugs were administered once daily for 28 days following which lipid profile was estimated on 28th day by using blood sample collected from the retro-orbital space.Results: STZ induced diabetes and also lead to dyslipidemia. Oral administration of CS seed extracts significantly lowered total cholesterol (TC), LDL:HDL ratio, TC:HDL ratio, thus, reducing the cardiovascular risk. HDL levels were slightly increased with CS seed extract compared to diabetic control group but not statistically significant. There was also statistically insignificant reduction in the atherogenic index with CS seed extract compared to diabetic control.Conclusions: CS seed extract (40 mg/kg) orally may have considerable therapeutic benefit as a hypolipidemic agent and can be suggested as a potential dietary add on.